Jul. 15 at 11:16 AM
$ANAB dropped by roughly 7% due to profit-taking and the unwinding of short-term gains, compounded by recent insider selling and a wider-than-expected first-quarter loss of -
$1.84 per share. The selloff occurred alongside a pullback in the broader biotechnology sector and institutional trading adjustments following the company's removal from several Russell indices.
Despite the single-session pullback, broader Wall Street sentiment remains constructive. Analyst consensus sits at a "Moderate Buy" with an average price target of
$81.82, as investors continue to look toward the ongoing legal developments regarding their Jemperli commercial agreements.
